Targeting the hypoxia paradox in neurodegeneration: A pharmacological roadmap across PHD inhibitors, HIF stabilizers, and stage-selective interventions
Hypoxia-inducible factor (HIF) signaling shows a dual, stage-dependent effect in the nervous system. Acute or mild oxygen deprivation activates HIF-1α-dependent programs that protect neurons; chronic or severe hypoxic stress turns the same pathway into a driver of mitochondrial dysfunction, oxidative injury, and neurodegeneration. This duality appears across Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and cerebral ischemia, and recent reviews have mapped its molecular determinants in detail. Building on this mechanistic foundation, we present a therapeutics-oriented account of how such staging could inform drug selection, framed as a hypothesis-generating translational framework rather than a validated clinical strategy. After summarizing the evidence for stage-dependent HIF signaling, we evaluated the pharmacological toolkit available or in development to act on it: prolyl hydroxylase domain inhibitors such as roxadustat, vadadustat, and daprodustat, developed for renal anemia and now candidates for neurological repurposing; selective HIF-2α antagonism, exemplified by the oncology drug belzutifan, proposed as an exploratory strategy for chronic-stage exposure; non-pharmacological hypoxic conditioning protocols; and adjunct strategies targeting phosphate and Tensin homolog-induced kinase 1/Parkin-dependent mitophagy. We reviewed clinical trial evidence on efficacy and on cardiovascular, hematologic, and oncologic safety, and outlined translational barriers still facing neurological application: blood–brain barrier penetration, the lack of biomarkers that can independently stage a patient’s hypoxic status, and the disappointing history of erythropoietin-based neuroprotection trials. We concluded with a conceptual roadmap for stage-selective research and identified the biomarker and trial-design work needed before pharmacological modulation of this HIF duality can be explored rationally in neurodegenerative disease.
Abdulkhaliq, A. A., Kim, B., Almoghrabi, Y. M., Khan, J., Ajoolabady, A., Ren, J., Bahijri, S., Tuomilehto, J., Borai, A., & Pratico, D. (2026). Amyloid-β and Tau in Alzheimer’s disease: Pathogenesis, mechanisms, and interplay. Cell Death & Disease, 17(1), Article 21. https://doi.org/10.1038/s41419-025-08186-8
Aderinto, N., Mbah, E. C., Halimat, A. A., Kolo, R. M., Tembo, W., Arumugam, H. K., Javed, A., Akinbo, O. E., Olalusi, M. P., & Egwu, E. O. (2026). Cerebrovascular Disease in Amyotrophic Lateral Sclerosis: Epidemiology, Mechanisms, and Clinical Implications. Sclerosis, 4(3), 18. https://doi.org/10.3390/sclerosis4030018
Bartnicki, P. (2024). Hypoxia-inducible factor prolyl hydroxylase inhibitors as a new treatment option for anemia in chronic kidney disease. Biomedicines, 12(8), 1884. https://doi.org/10.3390/biomedicines12081884
Bayne, A. N., & Trempe, J.-F. (2026). Molecular mechanisms of PINK1/Parkin-mediated mitochondrial quality control. Trends in Biochemical Sciences, 51(5), 474–490. https://doi.org/10.1016/j.tibs.2026.02.014
Blagov, A. V., Goncharov, A. G., Babich, O. O., Larina, V. V., Orekhov, A. N., & Melnichenko, A. A. (2022). Prospects for the development of Pink1 and Parkin activators for the treatment of Parkinson’s disease. Pharmaceutics, 14(11), 2514. https://doi.org/10.3390/pharmaceutics14112514
Boulares, A., Pichon, A., Faucher, C., Bragazzi, N. L., & Dupuy, O. (2024). Effects of intermittent hypoxia protocols on cognitive performance and brain health in older adults across cognitive states: A systematic literature review. Journal of Alzheimer’s Disease, 101(1), 13–30. https://doi.org/10.3233/JAD-240711
Burtscher, J., Duderstadt, Y., Gatterer, H., Burtscher, M., Vozdek, R., Millet, G. P., Hicks, A. A., Ehrenreich, H., & Kopp, M. (2024). Hypoxia sensing and responses in Parkinson’s disease. International Journal of Molecular Sciences, 25(3), 1759. https://doi.org/10.3390/ijms25031759
Camberos-Barraza, J., Alemán-Villa, K. M., & De la Herrán-Arita, A. K. (2026). Hypoxia, sleep architecture, and brain clearance: Converging pathways in neurodegenerative disease. Hypoxia Med, 026110001. https://doi.org/10.36922/HM026110001
Campla, C., Hoppe, G., Yu, M., Woda, J., Peachey, N. S., Josyula, V. P., Stauffer, S. R., & Sears, J. E. (2025). Characterization of hepatotropic small molecule inhibitors of hypoxia inducible factor prolyl hydroxylase in the prevention of oxygen-induced retinopathy. Journal of Medicinal Chemistry, 68(12), 12392–12401. https://doi.org/10.1021/acs.jmedchem.4c02186
Chang, W.-T., Lo, Y.-C., Gao, Z.-H., & Wu, S.-N. (2019). Evidence for the capability of roxadustat (FG-4592), an oral HIF prolyl-hydroxylase inhibitor, to perturb membrane ionic currents: An unidentified yet important action. International Journal of Molecular Sciences, 20(23), 6027. https://doi.org/10.3390/ijms20236027
Chen, D., Niu, Y., Liu, F., Yang, Y., Wang, X., Li, P., & Chen, X. (2023). Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: A systematic review and network meta-analysis. Frontiers in Pharmacology, 14, 1163908. https://doi.org/10.3389/fphar.2023.1163908
Chen, R. L., Ogunshola, O. O., Yeoh, K. K., Jani, A., Papadakis, M., Nagel, S., Schofield, C. J., & Buchan, A. M. (2014). HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice. Journal of Neurochemistry, 131(2), 177–189. https://doi.org/10.1111/jnc.12804
Chertow, G. M., Pergola, P. E., Farag, Y. M. K., Agarwal, R., Arnold, S., Bako, G., Block, G. A., Burke, S., Castillo, F. P., Jardine, A. G., Khawaja, Z., Koury, M. J., Lewis, E. F., Lin, T., Luo, W., Maroni, B. J., Matsushita, K., McCullough, P. A., Parfrey, P. S., … Eckardt, K.-U. (2021). Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD. New England Journal of Medicine, 384(17), 1589–1600. https://doi.org/10.1056/nejmoa2035938
Cho, H., Du, X., Rizzi, J. P., Liberzon, E., Chakraborty, A. A., Gao, W., Carvo, I., Signoretti, S., Bruick, R. K., Josey, J. A., Wallace, E. M., & Kaelin, W. G., Jr. (2016). On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. Nature, 539(7627), 107–111. https://doi.org/10.1038/nature19795
Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., Zojwalla, N. J., & Jonasch, E. (2021a). Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: A phase 1 trial and biomarker analysis. Nature Medicine, 27(5), 802–805. https://doi.org/10.1038/s41591-021-01324-7
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., Suárez, C., Hamzaj, A., Goh, J. C., Barrios, C., Richardet, M., Porta, C., Kowalyszyn, R., Feregrino, J. P., Żołnierek, J., … Motzer, R. J. (2021b). Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 384(9), 829–841. https://doi.org/10.1056/nejmoa2026982
Correia, S. C., Carvalho, C., Cardoso, S., et al. (2013). Defective HIF signaling pathway and brain response to hypoxia in neurodegenerative diseases: Not an “iffy” question! Current Pharmaceutical Design, 19(38), 6809–6822. https://doi.org/10.2174/1381612811319380013
Deeks, E. D. (2021). Belzutifan: First approval. Drugs, 81(16), 1921–1927. https://doi.org/10.1007/s40265-021-01606-x
Del Balzo, U., Signore, P. E., Walkinshaw, G., Seeley, T. W., Brenner, M. C., Wang, Q., Guo, G., Arend, M. P., Flippin, L. A., Chow, F. A., Gervasi, D. C., Kjaergaard, C. H., Langsetmo, I., Guenzler, V., Liu, D. Y., Klaus, S. J., Lin, A., & Neff, T. B. (2020). Nonclinical characterization of the hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat, a novel treatment of anemia of chronic kidney disease. Journal of Pharmacology and Experimental Therapeutics, 374(2), 342–353. https://doi.org/10.1124/jpet.120.265181
Devarasetty, P. P., Kunte, S. J., Dada, O., & Sparkle, T. (2022). Roxadustat: A narrative review of action and safety profile. J Anesth Clin Care, 9(1), 1-8. https://doi.org/10.24966/ACC-8879/100072
Dirnagl, U., Becker, K., & Meisel, A. (2009). Preconditioning and tolerance against cerebral ischaemia: From experimental strategies to clinical use. The Lancet Neurology, 8(4), 398–412. https://doi.org/10.1016/S1474-4422(09)70054-7
Eckardt, K.-U., Agarwal, R., Aswad, A., Awad, A., Block, G. A., Bacci, M. R., Farag, Y. M. K., Fishbane, S., Hubert, H., Jardine, A., Khawaja, Z., Koury, M. J., Maroni, B. J., Matsushita, K., McCullough, P. A., Lewis, E. F., Luo, W., Parfrey, P. S., Pergola, P., … Chertow, G. M. (2021a). Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. New England Journal of Medicine, 384(17), 1601–1612. https://doi.org/10.1056/nejmoa2025956
Eckardt, K.-U., Agarwal, R., Farag, Y. M. K., Jardine, A. G., Khawaja, Z., Koury, M. J., Luo, W., Matsushita, K., McCullough, P. A., Parfrey, P. S., Pergola, P. E., Roy-Chaudhury, P., Sarnak, M. J., Sharma, A., Spinowitz, B., Tumlin, J., Vargo, D. L., Walters, K. A., Winkelmayer, W. C., Chertow, G. M. (2021b). Global phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: Rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation, 36(11), 2039–2048. https://doi.org/10.1093/ndt/gfaa204
Ehrenreich, H., Kästner, A., Weissenborn, K., Streeter, J., Sperling, S., Wang, K. K. W., Worthmann, H., Hayes, R. L., von Ahsen, N., Kastrup, A., Jeromin, A., & Herrmann, M. (2011). Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients. Molecular Medicine, 17(11–12), 1306–1310. https://doi.org/10.2119/molmed.2011.00259
Ehrenreich, H., Weissenborn, K., Prange, H., Schneider, D., Weimar, C., Wartenberg, K., Schellinger, P. D., Bohn, M., Becker, H., Wegrzyn, M., Jähnig, P., Herrmann, M., Knauth, M., Bähr, M., Heide, W., Wagner, A., Schwab, S., Reichmann, H., Schwendemann, G., … Bartels, C. (2009). Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke. Stroke, 40(12). https://doi.org/10.1161/strokeaha.109.564872
Engelhardt, S., Patkar, S., & Ogunshola, O. O. (2014). Cell-specific blood-brain barrier regulation in health and disease: a focus on hypoxia. British Journal of Pharmacology, 171(5), 1210–1230. https://doi.org/10.1111/bph.12489
Fu, Z., Geng, X., Chi, K., Song, C., Wu, D., Liu, C., & Hong, Q. (2022). Efficacy and safety of daprodustat vs rhEPO for anemia in patients with chronic kidney disease: A meta-analysis and trial sequential analysis. Frontiers in Pharmacology, 13, 746265. https://doi.org/10.3389/fphar.2022.746265
Fujimaki, A., Ohuchi, K., Takizawa, S., Murakami, T., Kurita, H., Hozumi, I., Wen, X., Kitamura, Y., Wu, Z., Maekawa, Y., & Inden, M. (2023). The neuroprotective effects of FG-4592, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, against oxidative stress induced by alpha-synuclein in N2a cells. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-42903-7
Gaetani, L., Paolini Paoletti, F., Bellomo, G., Mancini, A., Simoni, S., Di Filippo, M., & Parnetti, L. (2020). CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. Trends in Pharmacological Sciences, 41(12), 1023–1037. https://doi.org/10.1016/j.tips.2020.09.011
Gallez, B. (2022). The role of imaging biomarkers to guide pharmacological interventions targeting tumor hypoxia. Frontiers in Pharmacology, 13, 853568. https://doi.org/10.3389/fphar.2022.853568
Gao, Y., Zhang, J., Tang, T., & Liu, Z. (2024). Hypoxia pathways in Parkinson’s disease: From pathogenesis to therapeutic targets. International Journal of Molecular Sciences, 25(19), 10484. https://doi.org/10.3390/ijms251910484
Haase V. H. (2013). Regulation of erythropoiesis by hypoxia-inducible factors. Blood reviews, 27(1), 41–53. https://doi.org/10.1016/j.blre.2012.12.003
Hirota, K. (2021). HIF-α prolyl hydroxylase inhibitors and their implications for biomedicine: A comprehensive review. Biomedicines, 9(5), 468. https://doi.org/10.3390/biomedicines9050468
Huang, X., Zhao, L., & Peng, R. (2022). Hypoxia-inducible factor 1 and mitochondria: An intimate connection. Biomolecules, 13(1), 50. https://doi.org/10.3390/biom13010050
Imai, E., & Imai, A. (2024). The comparison between vadadustat and daprodustat regarding dose, cost, and safety of treatment for renal anemia in non-dialysis patients with chronic kidney diseases. Intern Med, 63(13), 1841–1848. https://doi.org/10.2169/internalmedicine.2501-23
Jiang, B., Wang, X., Ma, J., Fayyaz, A., Wang, L., Qin, P., Ding, Y., Ji, X., & Li, S. (2024). Remote ischemic conditioning after stroke: Research progress in clinical study. CNS Neurosci Ther, 30(4), e14507. https://doi.org/10.1111/cns.14507
Jiang, B. H., & Hassan, K. (2026). Hypoxia-inducible factor 1 alpha in cancer: Discovery, regulation, mechanism, and clinical impact. Hypoxia Med, HM025520004. https://doi.org/10.36922/HM025520004
Johnson, H. N., & Prasad-Reddy, L. (2025). Daprodustat: A hypoxia-inducible factor-prolyl hydroxylase inhibitor for anemia of chronic kidney disease. The Annals of Pharmacotherapy, 59(1), 71–80. https://doi.org/10.1177/10600280241241563
Kaelin, W. G., Jr. (2022). Von Hippel-Lindau disease: Insights into oxygen sensing, protein degradation, and cancer. Journal of Clinical Investigation, 132(18), e162480. https://doi.org/10.1172/JCI162480
Kittur, F. S., Hung, C.-Y., Li, P.-A., Sane, D. C., & Xie, J. (2023). Asialo-rhuEPO as a potential neuroprotectant for ischemic stroke treatment. Pharmaceuticals (Basel), 16(4), 610. https://doi.org/10.3390/ph16040610
Kucharczyk, J., Bhatt, A., Bauer, L., & Economides, M. (2025). Belzutifan-associated hypoxia: A review of the novel therapeutic, proposed mechanisms of hypoxia, and management recommendations. International Journal of Molecular Sciences, 26(15), 7094. https://doi.org/10.3390/ijms26157094
Lei, L., Feng, J., Wu, G., Wei, Z., Wang, J. Z., Zhang, B., Liu, R., Liu, F., Wang, X., & Li, H. L. (2022). HIF-1α causes LCMT1/PP2A deficiency and mediates tau hyperphosphorylation and cognitive dysfunction during chronic hypoxia. International Journal of Molecular Sciences, 23(24), 16140. https://doi.org/10.3390/ijms232416140
Li, J., Yang, D., Li, Z., Zhao, M., Wang, D., Sun, Z., Wen, P., Dai, Y., Gou, F., Ji, Y., Zhao, D., & Yang, L. (2023). PINK1/Parkin-mediated mitophagy in neurodegenerative diseases. Ageing Research Reviews, 84, 101817. https://doi.org/10.1016/j.arr.2022.101817
Li, Y., Xu, Z., Tian, Z., Guo, M., Shao, Q., Liu, Y., Gu, Y., Jin, F., Ji, X., & Liu, J. (2026). Novel mechanism of neuronal hypoxia response: HIF-1α/STOML2-mediated PINK1-dependent mitophagy activation against neuronal injury. Cell Death Discovery, 12(1), 104. https://doi.org/10.1038/s41420-026-02960-z
Liu, B., Li, M., Zhang, L., Chen, Z., & Lu, P. (2022). Motor neuron replacement therapy for amyotrophic lateral sclerosis. Neural Regeneration Research, 17(8), 1633–1639. https://doi.org/10.4103/1673-5374.332123
Liu, C., He, W., & Zhang, J. (2025). Exercise regulates mitophagy to alleviate parkinsonian neurodegeneration. Frontiers in Aging Neuroscience, 17, 1678460. https://doi.org/10.3389/fnagi.2025.1678460
Lo, E., Cizmeci, M. N., Wilson, D., Ly, L. G., El-Shahed, A., Offringa, M., Pierro, A., & Kalish, B. T. (2025). Remote ischemic post-conditioning for neonatal encephalopathy: A safety and feasibility trial. Pediatric Research, 97(6), 1966–1975. https://doi.org/10.1038/s41390-024-03625-2
López-Hernández, B., Posadas, I., Podlesniy, P., Abad, M. A., Trullas, R., & Ceña, V. (2012). HIF-1α is neuroprotective during the early phases of mild hypoxia in rat cortical neurons. Experimental Neurology, 233(1), 543–554. https://doi.org/10.1016/j.expneurol.2011.11.040
Mendelson, S. J., & Prabhakaran, S. (2021). Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke: A Review. JAMA, 325(11), 1088–1098. https://doi.org/10.1001/jama.2020.26867
Miao, M., Wu, M., Li, Y., Zhang, L., Jin, Q., Fan, J., Xu, X., Gu, R., Hao, H., Zhang, A., & Jia, Z. (2022). Clinical potential of hypoxia inducible factor prolyl hydroxylase inhibitors in treating nonanemic diseases. Frontiers in Pharmacology, 13, 837249. https://doi.org/10.3389/fphar.2022.837249
Mikitsh, J. L., & Chacko, A. M. (2014). Pathways for small molecule delivery to the central nervous system across the blood-brain barrier. Perspectives in Medicinal Chemistry, 6, 11–24. https://doi.org/10.4137/PMC.S13384
Minutolo, R., Liberti, M. E., Simeon, V., Sasso, F. C., Borrelli, S., De Nicola, L., & Garofalo, C. (2024). Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: Meta-analysis of phase 3 randomized controlled trials. Clinical Kidney Journal, 17(1), sfad143. https://doi.org/10.1093/ckj/sfad143
Mitroshina, E. V., Strelkova, P. L., Korokozova, M. V., & Vedunova, M. V. (2026). HIF1 stabilization by roxadustat improves cognition and prevents neuron loss in Alzheimer’s disease in vivo. Biology (Basel), 15(14), 1118. https://doi.org/10.3390/biology15141118
Moreau, C., Gosset, P., Kluza, J., Brunaud-Danel, V., Lassalle, P., Marchetti, P., Defebvre, L., Destée, A., & Devos, D. (2011). Deregulation of the hypoxia inducible factor-1α pathway in monocytes from sporadic amyotrophic lateral sclerosis patients. Neuroscience, 172, 110–117. https://doi.org/10.1016/j.neuroscience.2010.10.040
Narendra, D. P., & Youle, R. J. (2024). The role of PINK1-Parkin in mitochondrial quality control. Nature Cell Biology, 26(10), 1639–1651. https://doi.org/10.1038/s41556-024-01513-9
Nyamukondiwa, M., Koneva, E. S., Achkasov, E. E., Zhang, X., Y, P. R., Beeraka, N. M., & Glazachev, O. S. (2025). Exploring hypoxia-induced neuroprotection mechanisms in post-stroke recovery. Translational Stroke Research, 16(6), 2298–2324. https://doi.org/10.1007/s12975-025-01364-y
Ogunshola, O. O., & Antoniou, X. (2009). Contribution of hypoxia to Alzheimer’s disease: is HIF-1alpha a mediator of neurodegeneration?. Cellular and Molecular Life Sciences, 66(22), 3555–3563. https://doi.org/10.1007/s00018-009-0141-0
Packer M. (2020). Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders. JACC. Basic to Translational Science, 5(9), 961–968. https://doi.org/10.1016/j.jacbts.2020.05.006
Pérez-Mato, M., López-Arias, E., Bugallo-Casal, A., Correa-Paz, C., Arias, S., Rodríguez-Yáñez, M., Santamaría-Cadavid, M., & Campos, F. (2024). New perspectives in neuroprotection for ischemic stroke. Neuroscience, 550, 30–42. https://doi.org/10.1016/j.neuroscience.2024.02.017
Porel, P., Bala, K., & Aran, K. R. (2025). Exploring the role of HIF-1α on pathogenesis in Alzheimer’s disease and potential therapeutic approaches. Inflammopharmacology, 33(2), 669–678. https://doi.org/10.1007/s10787-024-01585-x
Provenzano, R., Szczech, L., Leong, R., Saikali, K. G., Zhong, M., Lee, T. T., Little, D. J., Houser, M. T., Frison, L., Houghton, J., & Neff, T. B. (2021). Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non–Dialysis-Dependent CKD. Clinical Journal of the American Society of Nephrology, 16(8), 1190–1200. https://doi.org/10.2215/cjn.16191020
Purroy, F., Beretta, S., England, T. J., Hess, D. C., Pico, F., & Shuaib, A. (2022). Editorial: Remote ischemic conditioning (pre, per, and post) as an emerging strategy of neuroprotection in ischemic stroke. Frontiers in Neurology, 13, 932891. https://doi.org/10.3389/fneur.2022.932891
Puthusseri, S. P., Ravivarma, S., Johny, M., & Vengellur, A. (2026). Hypoxia-inducible factor-1α: Dual roles in maintaining neuronal homeostasis and neuronal degeneration via regulation of oxidative stress, mitochondrial dynamics, and bioenergetics. Journal of Physiology and Biochemistry, 82(1), 47. https://doi.org/10.1007/s13105-026-01187-x
Randy, H., Perrin, T. P., Ghaith, A., Kohlbrenner, D., Flore, P., Champigneulle, B., Guinot, M. F., Doutreleau, S., Verges, S., Brugniaux, J. V., & Marillier, M. (2025). Moderate intermittent hypoxic conditioning to enhance cerebrovascular function in the elderly: A randomized controlled trial. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 329(5), R805–R812. https://doi.org/10.1152/ajpregu.00160.2025
Reischl, S., Li, L., Walkinshaw, G., Flippin, L. A., Marti, H. H., & Kunze, R. (2014). Inhibition of HIF prolyl-4-hydroxylases by FG-4497 reduces brain tissue injury and edema formation during ischemic stroke. PLOS ONE, 9(1), e84767. https://doi.org/10.1371/journal.pone.0084767
Ren, X., Diao, X., Zhuang, J., & Wu, D. (2022). Structural basis for the allosteric inhibition of hypoxia-inducible factor (HIF)-2 by belzutifan. Molecular Pharmacology, 102(6), 240–247. https://doi.org/10.1124/molpharm.122.000525
Rosencrans, W. M., Lee, R. W., McGraw, L., Horsburgh, I., Wang, T.-Y., Quan, B., Huynh, D., Johnston, J. A., Chan, D. C., & Chou, T.-F. (2025). Putative PINK1/Parkin activators lower the threshold for mitophagy by sensitizing cells to mitochondrial stress. Science Advances, 11(35), eady0240. https://doi.org/10.1126/sciadv.ady0240
Sajjadi, E., Seven, Y. B., Ehrbar, J. G., Wymer, J. P., Mitchell, G. S., & Smith, B. K. (2022). Acute intermittent hypoxia and respiratory muscle recruitment in people with amyotrophic lateral sclerosis: A preliminary study. Experimental Neurology, 347, 113890. https://doi.org/10.1016/j.expneurol.2021.113890
Serebrovska, Z., Xi, L., Khetsuriani, M., Protsenko, O., Morozova, N., Tolstun, D. A., & Maksymchuk, O. (2025). Utility of Drosophila for studying hypoxia-inducible factor (HIF) in neurodegenerative diseases: Advantages versus limitations. Brain Research, 1867, 149953. https://doi.org/10.1016/j.brainres.2025.149953
Sharp, F. R., Ran, R., Lu, A., Tang, Y., Strauss, K. I., Glass, T., Ardizzone, T., & Bernaudin, M. (2004). Hypoxic preconditioning protects against ischemic brain injury. NeuroRx, 1(1), 26–35. https://doi.org/10.1602/neurorx.1.1.26
Singh, A. K., Carroll, K., McMurray, J. J. V., Solomon, S., Jha, V., Johansen, K. L., Lopes, R. D., Macdougall, I. C., Obrador, G. T., Waikar, S. S., Wanner, C., Wheeler, D. C., Więcek, A., Blackorby, A., Cizman, B., Cobitz, A. R., Davies, R., DiMino, T. L., Kler, L., … Perkovic, V. (2021). Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. New England Journal of Medicine, 385(25), 2313–2324. https://doi.org/10.1056/nejmoa2113380
Soares, P., Silva, C., Chavarria, D., Silva, F. S. G., Oliveira, P. J., & Borges, F. (2023). Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities. Ageing Research Reviews, 83, 101790. https://doi.org/10.1016/j.arr.2022.101790
Souvenir, R., Doycheva, D., Zhang, J. H., & Tang, J. (2015). Erythropoietin in stroke therapy: Friend or foe. Current Medicinal Chemistry, 22(10), 1205–1213. https://doi.org/10.2174/0929867322666150114152134
Stoumpos, S., Crowe, K., Sarafidis, P., Barratt, J., Bolignano, D., Del Vecchio, L., Małyszko, J., Więcek, A., Ortiz, A., & Cozzolino, M. (2024). Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: A clinical practice document by the European Renal Best Practice board of the European Renal Association. Nephrology Dialysis Transplantation, 39(10), 1710–1730. https://doi.org/10.1093/ndt/gfae075
Su, X., Xie, Y., Zhang, J., Li, M., Zhang, Q., Jin, G., & Liu, F. (2022). HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis. Cell Death & Disease, 13(10), 861. https://doi.org/10.1038/s41419-022-05304-8
Sugahara, M., Tanaka, T., & Nangaku, M. (2017). Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney International, 92(2), 306–312. https://doi.org/10.1016/j.kint.2017.02.035
Tada, S., Okuno, T., Shimizu, M., Sakai, Y., Sumi-Akamaru, H., Kinoshita, M., Yamashita, K., Sanda, E., Choong, C.-J., Namba, A., Sasaki, T., Koda, T., Takata, K., Miyagawa, S., Sawa, Y., Nakatsuji, Y., & Mochizuki, H. (2019). Single injection of sustained-release prostacyclin analog ONO-1301-MS ameliorates hypoxic toxicity in the murine model of amyotrophic lateral sclerosis. Scientific Reports, 9(1), 5252. https://doi.org/10.1038/s41598-019-41771-4
Tao, B., Gong, W., Xu, C., Ma, Z., Mei, J., & Chen, M. (2024). The relationship between hypoxia and Alzheimer’s disease: An updated review. Frontiers in Aging Neuroscience, 16, 1402774. https://doi.org/10.3389/fnagi.2024.1402774
Tashima, T. (2023). Proteolysis-targeting chimera (PROTAC) delivery into the brain across the blood-brain barrier. Antibodies (Basel), 12(3), 43. https://doi.org/10.3390/antib12030043
Timon, R., Martinez-Guardado, I., & Brocherie, F. (2023). Effects of intermittent normobaric hypoxia on health-related outcomes in healthy older adults: A systematic review. Sports Medicine - Open, 9(1), 19. https://doi.org/10.1186/s40798-023-00560-0
Tsai, T.-H., Lu, C.-H., Wallace, C. G., Chang, W.-N., Chen, S.-F., Huang, C.-R., Tsai, N.-W., Lan, M.-Y., Sung, P.-H., Liu, C.-F., & Yip, H.-K. (2015). Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: A randomized, prospective, placebo-controlled clinical trial. Critical Care, 19(1), 49. https://doi.org/10.1186/s13054-015-0761-8
Wang, H., Shi, X., Schenck, H., Hall, J. R., Ross, S. E., Kline, G. P., Chen, S., Mallet, R. T., & Chen, P. (2020). Intermittent hypoxia training for treating mild cognitive impairment: A pilot study. Am Journal of Alzheimer’s Disease Other Demen, 35, 1533317519896725. https://doi.org/10.1177/1533317519896725
Wang, L., & Xu, B. (2026). Rethinking PINK1/Parkin-mediated mitophagy in Parkinson’s disease: Functional continuity and activation-clearance uncoupling. Frontiers in Aging Neuroscience, 18, 1865383. https://doi.org/10.3389/fnagi.2026.1865383
Wang, Y. Y., Huang, Z. T., Yuan, M. H., Jing, F., Cai, R. L., Zou, Q., Pu, Y. S., Wang, S. Y., Chen, F., Yi, W. M., Zhang, H. J., & Cai, Z. Y. (2021). Role of hypoxia inducible factor-1α in Alzheimer’s disease. Journal of Alzheimer’s Disease, 80(3), 949–961. https://doi.org/10.3233/JAD-201448
Wen, H., Zuo, Y., Li, L., Zhan, L., Xue, J., Sun, W., & Xu, E. (2023). Hypoxic postconditioning restores mitophagy against transient global cerebral ischemia via Parkin-induced posttranslational modification of TBK1. Neurobiology of Disease, 179, 106043. https://doi.org/10.1016/j.nbd.2023.106043
Wu, X., Lazris, D., Wong, R., & Tykodi, S. S. (2025). Belzutifan for the treatment of renal cell carcinoma. Therapeutic Advances in Medical Oncology, 17, 17588359251317846. https://doi.org/10.1177/17588359251317846
Zhang, Q., Wang, Q., Jin, F., Huang, D., Ji, X., & Wang, Y. (2025). Intermittent hypoxia training improves cerebral blood flow without cognitive impairment. Annals of Clinical and Translational Neurology, 12(1), 86–96. https://doi.org/10.1002/acn3.52248
Zhang, Z., Yan, J., Chang, Y., ShiDu Yan, S., & Shi, H. (2011). Hypoxia inducible factor-1 as a target for neurodegenerative diseases. Current Medicinal Chemistry, 18(28), 4335–4343. https://doi.org/10.2174/092986711797200426
Zhu, L., Su, G., Li, R., Ma, T., Chen, W., Song, J., Wu, Q., An, Y., Wang, C., & Zhang, Z. (2025). The role of hypoxia/ischemia preconditioning in ischemic stroke. Neuroscience, 568, 343–354. https://doi.org/10.1016/j.neuroscience.2025.01.042
